This is a single arm, multi-center clinical trial. Target population is advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative, aiming to evaluate the efficacy and safety of the combination therapy of Cadonilimab and chemotherapy. Cadonilimab is a PD-1/CTLA-4 bi-specific antibody.
Patients with histologically/cytologically stage IIIB, IIIC, IV non-squamous Non-Small Cell Lung Cancer (NSCLC)
PD-L1 TPS<1%
Life expectancy more than 3 months
Without EGFR-sensitive mutation (19Exon del/21Exon L858R), ALK, ROS1 gene rearrangement or fusion
Histological examination with Small Cell Lung Cancer or squamous Non-Small Cell Lung Cancer
With active central nervous system (CNS) metastases confirmed by CT or MRI
With other malignancy within 3 years before enrollment
With severe infections within 4 weeks of the first dose of study treatment